ACC 26 - Dr Paul Sorajja (Banner Health in Phoenix, Phoenix, US) and Dr Lars Sondergaard (Chief Medical Officer and Divisional Vice President, Medical Affairs, Abbott) discuss the role of TriClip TEER in treating patients with severe tricuspid regurgitation and new data showcasing how TriClip TEER provides significant reduction in heart failure hospitalization relative to medical therapy.

Drawing on clinical trial data and real-world experience, Dr Sorajja weighs recent evidence from randomized trials including Tri.Fr, TRILUMINATE Pivotal, and TRISCEND II, and how to interpret these findings impact to clinical practice.

As interest in earlier treatment continues to grow, this discussion offers timely insight into where TriClip TEER may sit within the evolving strategy for severe tricuspid regurgitation.